共 50 条
- [31] Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup AnalysisBLOOD, 2020, 136Berdeja, Jesus G.Raje, Noopur S.Siegel, David S.Lin, YiAnderson, Larry D., Jr.Rodriguez-Otero, PaulaManier, SalomonEinsele, HermannCavo, MicheleTruppel-Hartmann, AnnaRowe, EvertonSanford, JillWang, JulieCampbell, Timothy B.Jagannath, Sundar
- [32] Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa TrialBLOOD, 2021, 138Shah, NinaMunshi, Nikhil C.Berdeja, Jesus G.Jagannath, SundarFinney, OliviaMartin, NathanAgarwal, AmitRowe, EvertonCampbe, Timothy B.San-Miguel, Jesus F.
- [33] Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional ExperienceBLOOD, 2022, 140 : 1856 - 1858Ferreri, Christopher J.Hildebrandt, Michelle A. T.Hashmi, HamzaShune, Leyla O.McGuirk, Joseph P.Sborov, Douglas W.Wagner, Charlotte B.Kocoglu, M. HakanAtrash, ShebliVoorhees, Peter M.Khouri, JackDima, DanaiAfrough, AimazSannareddy, AishwaryaSimmons, GaryDavis, JamesKalariya, NileshPeres, Lauren C.Alsina, MelissaLocke, Frederick L.Sidana, SurbhiHansen, Doris K.Patel, KrinaPuglianini, Omar Alexis Castaneda
- [34] Quality of life in patients (pts) with Relapsed and Refractory Multiple Myeloma (RRMM) treated with the BCMA-DIRECTED CAR T cell therapy Idecabtagene Vicleucel (IDE-CEL, bb2121): Results from the KarMMa trialONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 93 - 94Weisel, K.Einsele, H.Goldschmidt, H.Delforge, M.San Miguel, J.Bertin, K. B.Tahir, M.Lewis, H.Wang, J.Braverman, J.Campbell, T. B.Munshi, N.
- [35] French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): Update of the IFM Study from the Descar-T RegistryBLOOD, 2023, 142Cayla, SarahFerment, BenoitBigot, NoemieCaillot, DenisLafon, IngridKarlin, LionelLazareth, AnneTouzeau, CyrilleLeleu, XavierMoya, NielsHarel, StephaniePerrot, AuroreBories, PierreVincent, LaureLamure, SylvainMohty, MohamadMalard, FlorentManier, SalomonYakoub-Agha, IbrahimStoppa, Anne-MarieBrisou, GabrielDecaux, OlivierHouot, RochLe Gouill, StevenLambert, JeromeFacon, ThierryLoiseau, Herve AvetMoreau, PhilippeArnulf, Bertrand
- [36] Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): A KarMMa-3 Analysis in High-Risk SubgroupsCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S497 - S498Patel, KrinaRodriguez-Otero, PaulaManier, SalomonBaz, RachidRaab, Mark-SteffenCavo, MicheleCallander, NatalieCosta, Luciano J.Moreau, PhillippeSolomon, ScottChen, ChristineRaje, NoopurScheid, ChristophDelforge, MichelLarsen, JeremyPabst, ThomasSuzuki, KenshiTruppel-Hartmann, AnnaYang, ZhihongPiasecki, JuliaFelten, JasperCaia, AndreaCook, MarkGiralt, SergioMateos, Maria-Victoria
- [37] Idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): a KarMMa-3 high-risk subgroup analysisCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S56 - S57Patel, KrinaRodriguez-Otero, PaulaManier, SalomonBaz, RachidRaab, MarcCavo, MicheleCallander, NatalieCosta, LucianoMoreau, PhilippeSolomon, ScottChen, ChristineRaje, NoopurScheid, ChristophDelforge, MichelLarsen, JeremyPabst, Thomas MuellerSuzuki, KenshiTruppel-Hartmann, AnnaYang, ZhihongPiasecki, JuliaFelten, JasperCaia, AndreaCook, MarkGiralt, SergioMateos, Maria-Victoria
- [38] Characterization of Cytokine Release Syndrome in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple MyelomaBLOOD, 2020, 136Kansagra, AnkitLin, YiBerdeja, Jesus G.Shah, NinaOriol, AlbertYakoub-Agha, IbrahimEinsele, HermannRambaldi, AlessandroTruppel-Hartmann, AnnaRowe, EvertonWang, JulieAgarwal, AmitCampbell, Timothy B.Lonial, Sagar
- [39] Idecabtagene Vicleucel (ide-cel) versus Standard (std) Regimens in Patients (pts) with Triple-class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 247 - 248Scheid, ChristophRodriguez-Otero, PaulaAilawadhi, SikanderArnulf, BertrandPatel, KrinaCavo, MicheleNooka, Ajay K.Manier, SalomonCallander, NatalieCosta, Luciano J.Vij, RaviBahlis, Nizar J.Moreau, PhilippeSolomon, Scott R.Abrahamsen, Ingerid WeumBaz, RachidBroijl, AnnemiekChen, ChristineJagannath, SundarRaje, NoopurDelforge, MichelBenjamin, ReubenPabst, ThomasIida, ShinsukeBerdeja, JesusTruppel-Hartmann, AnnaBhatnagar, RashmiWu, FanPiasecki, JuliaEliason, LaurieDhanda, DevenderFelten, JasperCaia, AndreaCook, MarkMckiver, Mihaela PopaGiralt, Sergio
- [40] Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3BLOOD, 2023, 142Rodriguez Otero, PaulaAilawadhi, SikanderArnulf, BertrandPatel, Krina K.Cavo, MicheleNooka, Ajay K.Manier, SalomonCallander, Natalie S.Costa, LucianoVij, RaviBahlis, Nizar J.Moreau, PhilippeSolomon, Scott R.Abrahamsen, Ingerid WeumBaz, RachidBroijl, AnnemiekChen, ChristineJagannath, SundarRaje, Noopur S.Scheid, ChristofDelforge, MichelBenjamin, ReubenPabst, ThomasIida, ShinsukeBerdeja, Jesus G.Truppel-Hartmann, AnnaBhatnagar, RashmiWu, FanPiasecki, JuliaEliason, LaurieDhanda, DevenderFelten, JasperCaia, AndreaCook, MarkPopa-McKiver, MihaelaGiralt, Sergio A.